Terms: = Breast cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H
1789 results:
1. Epithelial Expressed b7-h4 Drives Differential Immunotherapy Response in Murine and Human breast cancer.
Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
[TBL] [Abstract] [Full Text] [Related]
2. [Evaluation of pd-l1 expression and intratumoral lymphocytic infiltration in triple-negative invasive breast carcinoma].
Barrios Barreto R; Silvera Redondo C; Garavito MDP; Ardila Pereira L
Medicina (B Aires); 2024; 84(2):227-235. PubMed ID: 38683507
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic Value of "Basal-like" Morphology, Tumor-Infiltrating Lymphocytes and Multi-MAGE-A Expression in Triple-Negative breast cancer.
Čeprnja T; Tomić S; Perić Balja M; Marušić Z; Blažićević V; Spagnoli GC; Juretić A; Čapkun V; Vuger AT; Pogorelić Z; Mrklić I
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674098
[TBL] [Abstract] [Full Text] [Related]
4. Chemotherapy-elicited extracellular vesicle CXCL1 from dying cells promotes triple-negative breast cancer metastasis by activating TAM/pd-l1 signaling.
Wang S; Li J; Hong S; Wang N; Xu S; Yang B; Zheng Y; Zhang J; Pan B; Hu Y; Wang Z
J Exp Clin Cancer Res; 2024 Apr; 43(1):121. PubMed ID: 38654356
[TBL] [Abstract] [Full Text] [Related]
5. Tumor-associated macrophage subtypes on cancer immunity along with prognostic analysis and SPP1-mediated interactions between tumor cells and macrophages.
Xu L; Chen Y; Liu L; Hu X; He C; Zhou Y; Ding X; Luo M; Yan J; Liu Q; Li H; Lai D; Zou Z
PLoS Genet; 2024 Apr; 20(4):e1011235. PubMed ID: 38648200
[TBL] [Abstract] [Full Text] [Related]
6. Clinical relevance of glycosylation in triple negative breast cancer: a review.
Chakraborty M; Kaur J; Gunjan ; Kathpalia M; Kaur N
Glycoconj J; 2024 Apr; 41(2):79-91. PubMed ID: 38634956
[TBL] [Abstract] [Full Text] [Related]
7. Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns.
Gougis P; Hamy AS; Jochum F; Bihan K; Carbonnel M; Salem JE; Dumas E; Kabirian R; Grandal B; Barraud S; Coussy F; Hotton J; Savarino R; Marabelle A; Cadranel J; Spano JP; Laas E; Reyal F; Abbar B
JAMA Netw Open; 2024 Apr; 7(4):e245625. PubMed ID: 38630478
[TBL] [Abstract] [Full Text] [Related]
8. Contribution of tumour and immune cells to pd-l1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119.
Cortes J; Winer EP; Lipatov O; Im SA; Gonçalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Hund S; Kulangara K; Karantza V; Mejia JA; Ma J; Jelinic P; Huang L; Pruitt SK; Emancipator K
J Pathol Clin Res; 2024 May; 10(3):e12371. PubMed ID: 38627977
[TBL] [Abstract] [Full Text] [Related]
9. CCAAT enhancer binding protein delta activates vesicle associated membrane protein 3 transcription to enhance chemoresistance and extracellular pd-l1 expression in triple-negative breast cancer.
Zhao Y; Yu Y; Li X; Guo A
J Exp Clin Cancer Res; 2024 Apr; 43(1):115. PubMed ID: 38627816
[TBL] [Abstract] [Full Text] [Related]
10. Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and pd-l1 enhances antitumor responses.
Tapia-Galisteo A; Sánchez-Rodríguez I; Narbona J; Iglesias-Hernández P; Aragón-García S; Jiménez-Reinoso A; Compte M; Khan S; Tsuda T; Chames P; Lacadena J; Álvarez-Vallina L; Sanz L
Oncoimmunology; 2024; 13(1):2338558. PubMed ID: 38623463
[TBL] [Abstract] [Full Text] [Related]
11. OMA1 competitively binds to HSPA9 to promote mitophagy and activate the cGAS-STING pathway to mediate GBM immune escape.
Zhu W; Rao J; Zhang LH; Xue KM; Li L; Li JJ; Chen QZ; Fu R
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604814
[TBL] [Abstract] [Full Text] [Related]
12. Purine metabolism in lung adenocarcinoma: A single-cell analysis revealing prognostic and immunotherapeutic insights.
Zhang P; Pei S; Zhou G; Zhang M; Zhang L; Zhang Z
J Cell Mol Med; 2024 Apr; 28(8):e18284. PubMed ID: 38597415
[TBL] [Abstract] [Full Text] [Related]
13. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
Kim YN; Chung YS; Park E; Lee ST; Lee JY
Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
[TBL] [Abstract] [Full Text] [Related]
14. Blocking senescence and tolerogenic function of dendritic cells induced by γδ Treg cells enhances tumor-specific immunity for cancer immunotherapy.
Si F; Liu X; Tao Y; Zhang Y; Ma F; Hsueh EC; Puram SV; Peng G
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580332
[TBL] [Abstract] [Full Text] [Related]
15. Suppression of AGRN enhances CD8+ T cell recruitment and inhibits breast cancer progression.
Tao J; Shen L; Zhuang M; Zhai C; Zeng H; Mao Y; Liu X
FASEB J; 2024 Apr; 38(7):e23582. PubMed ID: 38568853
[TBL] [Abstract] [Full Text] [Related]
16. Comprehensive analysis of fibroblast activation protein expression across 23 tumor indications: insights for biomarker development in cancer immunotherapies.
Dziadek S; Kraxner A; Cheng WY; Ou Yang TH; Flores M; Theiss N; Tsao TS; Andersson E; Harring SV; Bröske AE; Ceppi M; Teichgräber V; Charo J
Front Immunol; 2024; 15():1352615. PubMed ID: 38558814
[TBL] [Abstract] [Full Text] [Related]
17. [Clinicopathological characteristics and immune microenvironment of breast squamous cell carcinoma].
Liang JY; Wang YM; Wen Z; Zhang WH; Gao ZZ; Wang Z; Guo SP
Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):337-343. PubMed ID: 38556816
[No Abstract] [Full Text] [Related]
18. Associations of PD-1 and pd-l1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.
Yang M; Liu Y; Zheng S; Geng P; He T; Lu L; Feng Y; Jiang Q
Aging (Albany NY); 2024 Mar; 16(7):6068-6097. PubMed ID: 38546391
[TBL] [Abstract] [Full Text] [Related]
19. Formononetin Restrains Tumorigenesis of breast Tumor by Restraining STING-NF-κB and Interfering with the Activation of pd-l1.
Liu H; Wang Z; Liu Z
Discov Med; 2024 Mar; 36(182):613-620. PubMed ID: 38531802
[TBL] [Abstract] [Full Text] [Related]
20. Harnessing PD-1 cell membrane-coated paclitaxel dimer nanoparticles for potentiated chemoimmunotherapy.
Hu N; Xue H; Zhang T; Fan Y; Guo F; Li Z; Huo M; Guan X; Chen G
Biomed Pharmacother; 2024 May; 174():116482. PubMed ID: 38520866
[TBL] [Abstract] [Full Text] [Related]
[Next]